Replies to post #273525 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

It's the Iceberg Thing.

Important to write your post word for word to Missling, an additional marketing opportunity AND a good reasoning for approval as a first useage for A-73 (maybe they know already).

Thanks. But I'll communicate with Dr. Missling or any of the Anavex principals if they give me a call or email. Not expecting any such contacts.

I've contended all along (about 5 years or so?) that the Anavex people know a whole lot more about their molecules than they reveal. Simply, two crucial factors: a) sigma-1 receptor protein activation produces a multitude of positive, "downstream" physiological and biochemical outcomes in neurons, nerves, and organ systems, and b) the unique, proprietary sigma-1 receptor agonists of Anavex Life Sciences Corp are both unique and optimal in their activation of these proteins. Nothing else approaches their activity.

I have no inside knowledge of what Anavex knows. But as a biologist usefully knowledgeable of the arcane details of the molecular biology and the biochemistries of neurons, I understand how sigma-1 receptor protein activation can produce so many favorable outcomes. Be assured, they are not confined to just three diseases, Rett syndrome, Parkinson's disease dementia, or Alzheimer's. Anavex is running human clinical trials for each of those. But a number of other pathologies are targeted in the company's pipeline.

But any biology grad student, after spending a few days taking in all of the available Anavex information (I've spent many days on this) could see all sorts of new therapeutic applications. Doubtless, Anavex insiders envision many new, other things for which their sigma-1 receptor agonists could target; not just a few central nervous system diseases.

In this regard, I've also contended that any number of exploratory, preliminary tests of these applications have already been conducted on murines, lab rodents, behind locked doors (by external investigating teams who had to sign NDAs, non-disclosure agreements). I know biological research. I'm doing some of it myself, on a nice federal grant, to solve an unrelated but significant environmental problem. The people taking biological science forward do not confine their thoughts and explanations and visions constrained by "accepted practice." They think outside of the petri dish, unrestrained by conventional practice or perspective. "Hey! Look at that! (Sigma-1 receptor activation, for example). Let's see what happens if I do this...."

None of that has to be tried out on humans. Lab rats and mice work just fine. Fail with them, the idea is nixed. But with success, try it in humans some day.

Some time ago I deliberated a bit on potential veterinary applications for Anavex. Gigantic market. Similar, but more accomplished biological minds at Anavex have surely imagined the same things.

Any evidence for any of the above? Just one inadvertent phrase about Anavex spoken some time ago by Dr. Christopher Missling, to the effect, "Like an iceberg."